Human Genome’s Lupus Drug Surprises Analysts
Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.
Featured Articles
Special Report: Fighting the U.S. AIDS Epidemic
An estimated 1.2 million people in the U.S. have the HIV virus. OneMedPlace speaks with AIDS advocate Michael Manganiello about the scope of the epidemic, the possibility of a vaccine, and what needs to happen to make a national AIDS strategy a reality.
Medtronic Files for Pre-Market Approval for Epilepsy Device
Medtronic Deep-Brain Stimulation(DBS) Therapy is designed to treat patients with uncontrollable seizures who do not respond to medication.
CSI Enrolls First Patient in Study of Vascular Device
Cardiovascular Systems, a medical device company that specializes in the treatment of vascular diseases, has enrolled the first patient in its COMPLIANCE 360° clinical trial.
New Developments in Detecting and Treating Alzheimer’s
Every 70 seconds, someone develops Alzheimer’s disease. This startling figure from the Alzheimer’s Association underlines the desperate need for new tools to diagnose and treat this debilitating illness.
FDA Approves First Maintenance Therapy Drug for Lung Cancer
Two pharmaceutical companies are eager to advance a different approach to treating lung cancer.
CBCE Launches Continuing Education App for iPhone
The new app allows for fully accredited multimedia CME content such as treatment updates, conference highlights, and tests.
Foresight’s Conjunctivitis Solution Beats Competitors In Study
FST-100 performed significantly better than other treatments for adenoviral conjunctivitis, including the current experimental “gold standard” topical cidofovir.
FDA to Review Alternative Dosing Method for Bone Marrow Drug
Most people have never heard of myelodysplastic syndrome (MDS), but approximately 10,000 to 15,000 people in the U.S. are diagnosed with it every year.
Independent Study Validates BioNeutral’s Ygiene
In an independent study, BioNeutral’s Ygiene antimicrobial formulation eliminated a particularly dangerous type of mold in record time.